HBA2 rs121912656: Understanding Hemoglobin Constant Spring
The HBA2 rs121912656 variant, widely known as Hemoglobin Constant Spring (HbCS), is a genetic change that disrupts the normal termination of the alpha-globin protein. This variant is primarily associated with alpha-thalassemia phenotypes, particularly when inherited alongside other alpha-globin gene deletions.
What each genotype means
Typical alpha-globin expression
This genotype represents the standard, non-mutated sequence for the HBA2 gene termination site. Individuals with this profile do not carry the Hemoglobin Constant Spring mutation and are not at risk for alpha-thalassemia associated with this specific variant.
This is the most common genotype globally, found in the vast majority of the human population.
Hemoglobin Constant Spring carrier
You carry one copy of the Hemoglobin Constant Spring mutation, which affects the termination of the alpha-globin protein. While typically asymptomatic on its own, this variant can lead to alpha-thalassemia phenotypes, such as Hb H disease, if inherited alongside certain alpha-globin deletion alleles. You should discuss your carrier status with a genetic counselor or clinician, especially if you are planning a pregnancy.
This genotype is common in Southeast Asian populations, with carrier frequencies reaching up to 5-8% in some regions.
Homozygous Hemoglobin Constant Spring
You carry two copies of the Hemoglobin Constant Spring mutation. This condition is associated with unstable alpha-globin mRNA and can result in clinical manifestations ranging from mild anemia to more severe hemolysis. The severity of the phenotype can be influenced by other genetic factors, so consultation with a hematologist is recommended to understand your specific health profile.
This genotype is rare, occurring primarily in populations where the carrier frequency is high, such as in Southeast Asia.
What is the rs121912656 Variant?
The variant rs121912656, often referred to in medical literature as Hemoglobin Constant Spring (HbCS), is a specific point mutation located within the HBA2 gene. In this variant, a single nucleotide change (c.427T>C) alters the gene's stop codon. Normally, a stop codon signals the cellular machinery to finish building a protein. By disrupting this signal, the mutation causes the cell to continue adding amino acids to the alpha-globin chain, resulting in an abnormally elongated and unstable protein. This structural change is significant because it interferes with the normal assembly of hemoglobin, the vital protein in red blood cells responsible for transporting oxygen throughout the body.
The Role of the HBA2 Gene
The HBA2 gene provides the instructions for creating the alpha-globin protein, which is a fundamental component of hemoglobin. Hemoglobin is a complex molecule made of four protein subunits: two alpha-globin chains and two beta-globin chains. These subunits work together to bind oxygen in the lungs and release it into tissues. Because the HBA2 gene is essential for producing these alpha-globin chains, any mutation that affects its function can lead to a reduction in the amount of functional hemoglobin produced. This condition is broadly categorized as alpha-thalassemia. When the HBA2 gene is compromised, the body may struggle to maintain healthy red blood cell function, potentially leading to anemia or other related blood disorders.
Research and Clinical Associations
Research has established that the HbCS variant is clinically significant, particularly when it interacts with other genetic factors. While individuals who carry only one copy of the HbCS variant may show few symptoms, the clinical picture changes significantly when it is inherited alongside an alpha-thalassemia deletion. This combination can lead to Hemoglobin H (HbH) disease, a form of chronic hemolytic anemia. The evidence for this association is well-documented in clinical genetics, though the severity of the phenotype can vary between individuals. Because this is a complex genetic trait, it is important to note that the presence of this variant does not automatically guarantee a specific health outcome. Individuals concerned about their genetic status or potential symptoms should consult with a medical professional or a genetic counselor for personalized evaluation.
Population Frequency
The rs121912656 variant is not distributed evenly across the globe. It is most commonly observed in populations throughout Southeast Asia, where the allele frequency can reach as high as 5% to 8% in certain regions. Because of this higher prevalence, screening for this variant is often prioritized in clinical settings serving these populations, especially during prenatal or family planning consultations. The variant is considered a founder mutation in these areas, meaning it has been passed down through generations within specific ancestral groups. Understanding this geographic distribution helps clinicians better assess the likelihood of the variant being present in patients with unexplained anemia or those undergoing routine genetic screening.
Managing Genetic Information
Information about genetic variants like rs121912656 is intended for educational purposes and should not be used to self-diagnose or make medical decisions. If you have received results indicating you carry this variant, it is essential to discuss the findings with a qualified healthcare provider or a clinical geneticist. They can provide context based on your full genetic profile and family history. It is also important to remember that genetic testing results are only one piece of the puzzle; clinical symptoms, blood tests, and physical examinations are equally critical in understanding your health. Never change or stop any prescribed medication based on genetic information without first consulting your doctor or pharmacist, as they are the only ones qualified to interpret these results in the context of your overall medical care.
How common is this variant?
The rs121912656 variant is common in Southeast Asian populations, with an allele frequency reaching up to 5-8%.
Frequently asked questions
What is Hemoglobin Constant Spring?
Hemoglobin Constant Spring is a specific genetic variant in the HBA2 gene that causes the alpha-globin protein to be longer than normal. This instability can lead to alpha-thalassemia, a condition affecting red blood cell health.
Is rs121912656 the same as HbCS?
Yes, rs121912656 is the SNP identifier for the genetic change that results in the Hemoglobin Constant Spring protein variant. They refer to the same underlying genetic alteration.
Can this variant cause anemia?
Yes, when inherited with other alpha-thalassemia mutations, this variant can contribute to Hemoglobin H disease, which is a form of chronic hemolytic anemia. The severity depends on the other genetic factors present.
Should I be tested for this variant?
Genetic testing is typically recommended by healthcare providers if there is a family history of thalassemia or if a patient shows signs of unexplained anemia. You should discuss the necessity of testing with your doctor.
Sources & further reading
Educational information only, last refreshed 9/20/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121912656?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29